Alnylam Pharmaceuticals, Inc. (ALNY) vs Regeneron Pharmaceuticals, Inc. (REGN)
- Alnylam Pharmaceuticals, Inc. ALNY 231.83 −0.94%
- Regeneron Pharmaceuticals, Inc. REGN 790.74 −0.70%
Alnylam Pharmaceuticals, Inc. and Regeneron Pharmaceuticals, Inc. are both Biotechnology companies. Regeneron Pharmaceuticals, Inc. is the larger, with a market value of $82.0B against $31.3B — 2.6× the size. Regeneron Pharmaceuticals, Inc. trades at the lower P/E: 18.9× against 39.5×. Alnylam Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 95.1% against 9.29%. Regeneron Pharmaceuticals, Inc. has the higher net margin (27.9% vs 16.1%) and the higher return on invested capital (9.34% vs 0.00%). Across the 22 metrics below, Regeneron Pharmaceuticals, Inc. leads on 16 and Alnylam Pharmaceuticals, Inc. on 6.
Valuation
Profitability
| Metric | ALNY | REGN | Biotechnology median |
|---|---|---|---|
| Gross margin | 79.65% | 84.86% | 65.16% |
| Operating margin | 20.81% | 24.74% | 0.00% |
| Net margin | 16.13% | 27.86% | 0.00% |
| Free cash flow margin | 17.07% | 23.01% | 0.00% |
| Return on equity | 96.55% | 14.04% | (56.36%) |
| Return on assets | 15.30% | 10.83% | (48.04%) |
| Return on invested capital | 0.00% | 9.34% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack